Stocktoria

BIOMARIN PHARMACEUTICAL INC BMRN

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1999-07-23 · LEI

BIOMARIN PHARMACEUTICAL INC statistics & valuation

Market cap$11.4B
P / E32.7×
P / S3.5×
P / B1.9×
P / FCF15.7×
Net margin10.8%
Return on equity5.7%
FCF margin22.5%
Net cash$714.5M
Net debt / EBITDA-1.5×
Enterprise value USD$10.7B
EV / EBITDA21.9×
Earnings yield EBIT/EV3.8%
Return on capital6%
Graham number -49.7%$35.34

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($35.34); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
-56.40% -8.90% -5.20% -1.40% 45.90% -3.50% 6.80% 6.90% 15.00% 10.80% 2016201720182019202020212022202320242025
Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
-71.90% -1.10% -8.30% -5.90% -2.30% -4.50% 7.70% 7.70% 17.00% 12.70% 2016201720182019202020212022202320242025
Return on equity (%)
-22.80% -4.20% -2.60% -0.80% 20.80% -1.50% 3.10% 3.40% 7.50% 5.70% 2016201720182019202020212022202320242025
Shares outstanding
172.6M 175.8M 178.3M 179.8M 191.7M 183.9M 189.0M 191.6M 196.7M 197.4M 2016201720182019202020212022202320242025
Net debt ($)
-$714.5M 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-15.70% -2.50% -1.70% -0.50% 14.60% -1.10% 2.20% 2.50% 6.10% 4.60% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-33.70% -15.80% -8.30% -5.70% -1.60% 11.30% 2.60% 2.60% 17.10% 22.50% 2016201720182019202020212022202320242025
Debt / equity (×)
0.10× 2016201720182019202020212022202320242025
EPS ($)
-$3.81 -$0.67 -$0.44 -$0.13 $4.50 -$0.35 $0.75 $0.87 $2.21 $1.80 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

BIOMARIN PHARMACEUTICAL INC trades at about 39× earnings — above its 10-year norm (10-year range 18.4×–153.8×, median 31.4×).

18.4× 153.8×

Shaded band = 10-year range (18.4×–153.8×); dot = today's 39×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin12.7%17.0%7.7%7.7%-4.5%-2.3%-5.9%-8.3%-1.1%-71.9%
Net margin10.8%15.0%6.9%6.8%-3.5%45.9%-1.4%-5.2%-8.9%-56.4%
FCF margin22.5%17.1%2.6%2.6%11.3%-1.6%-5.7%-8.3%-15.8%-33.7%
Return on assets4.6%6.1%2.5%2.2%-1.1%14.6%-0.5%-1.7%-2.5%-15.7%
Return on equity5.7%7.5%3.4%3.1%-1.5%20.8%-0.8%-2.6%-4.2%-22.8%
Debt / equity0.10×—————————
Current ratio5.215.332.514.674.164.762.083.932.703.24

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.